Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.
Fujitani S, Sun HY, Yu VL, Weingarten JA.
Chest. 2011 Apr;139(4):909-919. doi: 10.1378/chest.10-0166.
Nebulized Antibiotics for Multidrug-Resistant Ventilator-Associated Pseudomonas aeruginosa Pneumonia.
Gilbert DN.
Crit Care Med. 2019 Jun;47(6):880-881. doi: 10.1097/CCM.0000000000003751.
Too Much or Too Little Empiric Treatment for Pseudomonas aeruginosa in Community-acquired Pneumonia?
Torres A, Niederman MS.
Ann Am Thorac Soc. 2021 Sep;18(9):1456-1458. doi: 10.1513/AnnalsATS.202107-762ED.
Pseudomonas aeruginosa: acute lung injury or ventilator-associated pneumonia?
Berra L, Sampson J, Wiener-Kronish J.
Minerva Anestesiol. 2010 Oct;76(10):824-32.
A Mouse Model of Pseudomonas aeruginosa Pneumonia.
LeBlanc BW, Lefort CT.
Methods Mol Biol. 2021;2321:53-61. doi: 10.1007/978-1-0716-1488-4_6.
Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: a systematic review and meta-analysis.
Ding C, Yang Z, Wang J, Liu X, Cao Y, Pan Y, Han L, Zhan S.
Int J Infect Dis. 2016 Aug;49:119-28. doi: 10.1016/j.ijid.2016.06.014. Epub 2016 Jun 18.
[Pneumonia due to Pseudomonas aeruginosa].
Vallés J, Mariscal D.
Enferm Infecc Microbiol Clin. 2005 Dec;23 Suppl 3:30-6. doi: 10.1157/13091218.
Impact of Pseudomonas aeruginosa coverage on the prognosis of elderly patients with community-acquired pneumonia.
Goto A, Komiya K, Umeki K, Hiramatsu K, Kadota JI.
J Infect Chemother. 2023 Jan;29(1):55-60. doi: 10.1016/j.jiac.2022.09.016. Epub 2022 Sep 24.
alpha-Tocopherol Attenuates the Severity of Pseudomonas aeruginosa-induced Pneumonia.
Wagener BM, Anjum N, Evans C, Brandon A, Honavar J, Creighton J, Traber MG, Stuart RL, Stevens T, Pittet JF.
Am J Respir Cell Mol Biol. 2020 Aug;63(2):234-243. doi: 10.1165/rcmb.2019-0185OC.
Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.
Rahdar HA, Kazemian H, Bimanand L, Shahraki-Zahedani S, Feyisa SG, Taki E, Havaei SA, Karami-Zarandi M.
Infect Disord Drug Targets. 2018;18(3):249-254. doi: 10.2174/1871526518666180410122531.
